As FGF23 is known to cause impaired bone mineralization in MDS and chronic kidney disease, and as it also acts as a negative regulator of erythropoiesis in vivo35,36, we analyzed FGF23 expression in Ctnnb1OE-SEC mice in more detail. This evidence concerns the gene FGF23 and myelodysplastic syndrome.